UFC blocks payment to Silva for failing drug test - report | Inquirer Sports

UFC blocks payment to Silva for failing drug test – report

By: - Reporter / @MarkGiongcoINQ
/ 02:35 PM February 09, 2015

MANILA, Philippines — The Ultimate Fighting Championship (UFC) has reportedly withheld roughly $6 million payment to former middleweight champion Anderson Silva for failing his pre-fight drug test.

Silva tested positive for two anabolic steroids, drostanolone and androstane. The results came just three days after making a triumphant return from a broken leg he suffered in a title fight against Chris Weidman on Dec. 28, 2013.

Silva won via unanimous decision over Nick Diaz, who is also facing a doping issue, last Feb. 1 (Manila time) in the main event of UFC 183 at the MGM Grand Garden in Las Vegas – a win that will likely be overturned to a no-contest following the findings.

Article continues after this advertisement

In a prepared statement, Silva denied taking performance-enhancing drugs before his fight with Diaz.

FEATURED STORIES

“I’ve been competing in this sport for a very long time. This is my 19th fight in the UFC. I have been thoroughly tested many times and have never had a positive drug test,” the statement read as posted on foxsports.com.
RELATED STORIES
Returning Silva dominates Diaz in UFC 183 unanimous decision win

Silva, Diaz test positive for illegal substances after UFC 183

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Anderson Silva, Chris Weidman, Doping, drug test, Mixed Martial Arts, MMA, Nick Diaz, Sports, UFC

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.